Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 7, 2013 - Issue
Submit an article Journal homepage
516
Views
91
CrossRef citations to date
0
Altmetric
Review

Aflibercept in wet AMD: specific role and optimal use

F Semeraro1 Department of Medical and Surgical Specialties, Radiological Specialties and Public Health, Ophthalmology Clinic, University of Brescia, Brescia, ItalyCorrespondence[email protected]
,
F Morescalchi1 Department of Medical and Surgical Specialties, Radiological Specialties and Public Health, Ophthalmology Clinic, University of Brescia, Brescia, Italy
,
S Duse1 Department of Medical and Surgical Specialties, Radiological Specialties and Public Health, Ophthalmology Clinic, University of Brescia, Brescia, Italy
,
F Parmeggiani2 Department of Ophthalmology, University of Ferrara, Ferrara, Italy
,
E Gambicorti1 Department of Medical and Surgical Specialties, Radiological Specialties and Public Health, Ophthalmology Clinic, University of Brescia, Brescia, Italy
&
C Costagliola3 Department of Health Science, Ophthalmology Clinic, University of Molise, Campobasso, Italy
Pages 711-722 | Published online: 05 Aug 2013

Figures & data

Figure 1 Diagram showing the structure of the vascular endothelial growth factor receptor-1 and -2 and the structure of aflibercept (VEGF Trap-eye).

Notes: Aflibercept (VEGF Trap-eye) is generated by a fusion that includes the second binding domain of vascular endothelial growth factor receptor (VEGFR)-1 and the third binding domain of VEGFR-2 attached to a FC fragment of a human IgG.
Abbreviation: FC, fragment crystallizable region.
Figure 1 Diagram showing the structure of the vascular endothelial growth factor receptor-1 and -2 and the structure of aflibercept (VEGF Trap-eye).

Figure 2 Vascular endothelial growth factor binds to two vascular endothelial growth factor receptors which induces the angiogenic response by activating the tyrosine kinase.

Notes: vascular endothelial growth factor receptor (VEGFR)-2 is shown. Aflibercept (VEGF Trap-eye) binds all vascular endothelial growth factor (VEGF) isoforms more tightly than their native receptors, thus preventing binding of VEGF to its cognate receptors.
Figure 2 Vascular endothelial growth factor binds to two vascular endothelial growth factor receptors which induces the angiogenic response by activating the tyrosine kinase.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.